|Table of Contents|

Clinical characteristics and prognosis of primary central nervous system lymphoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 18
Page:
3437-3442
Research Field:
Publishing date:

Info

Title:
Clinical characteristics and prognosis of primary central nervous system lymphoma
Author(s):
GAO Jing; HAO Miaowang; YAN Xueqian; JI Yueru; TIAN Jing; XIAO Fang; LIU Li
Department of Hematology,Second Affiliated Hospital of Air Force Military Medical University,Shaanxi Xi'an 710038,China．
Keywords:
primary central nervous system lymphoma; clinical features; prognostic analysis
PACS:
R733.4
DOI:
10.3969/j.issn.1672-4992.2023.18.019
Abstract:
Objective:To analyze the clinical characteristics and the prognostic factors of the patients with primary central nervous system lymphoma (PCNSL).Methods:Collect the clinical data and survival status of 50 PCNSL patients treated in our hospital from February 2014 to June 2021.SPSS 26.0 was used for data collation,statistics and analysis.Variables with statistically significant differences in univariate analysis were used as independent variables in Cox regression to analyze prognostic risk factors and draw survival curves.Results:Among the 50 patients,there were 32 males and 18 females,median age was 61.5 years old (24～73 years old).The ECOG score of 0～1 points in 18 cases and ≥2 points in 32 cases.The IELSG score of 0～1 points in 15 cases,2～3 points in 27 cases and 4～5 points in 8 cases,there were 54.0% of the patients in the middle risk group.The main pathological types were diffuse large B-cell lymphoma (non-GCB) (82.0%).Pathological examination showed that Ki-67≥90% in 14 cases.The LDH≥250 U/L in 15 cases.The number of lesions was mainly multiple,accounting for 66.0%,and deep lesions were involved in 26 cases,accounting for 52.0%.Clinical manifestations were typical of the increase of intracranial pressure,and 22 cases (44%) were headache,dizziness,nausea and vomiting.The treatment regiments were single MTX in 19 cases,R+MTX in 15 cases,and R+MTX+BTKi in 16 cases.Univariate analysis showed that the 3-year survival rate of patients ≤60 years old,ECOG <2 points,no deep lesions involved,low risk group,LDH <250 U/L was higher than that of the control group.The median survival time of patients treated with R+MTX+BTKi was (66.69±4.18) months,and that of the R+MTX group was (44.93±8.25) months.Single MTX group was (28.58±6.50) months.Cox proportional risk regression analysis showed that the risk of death was relatively high in patients with more than 60 years old,multiple pathogenesis,deep lesions and monotherapy.Conclusion:The prognosis of PCNSL is related to age,number of lesions,involvement of deep lesions and treatment project.The addition of BTK inhibitors can improve the disease prognosis.

References:

［1］SUH HB,CHOI YS,BAE S,et al.Primary central nervous system lymphoma and atypical glioblastoma:Differentiation using radiomics approach［J］.European Radiology,2018,28(9):3832-3839.
［2］HATTORI K,SAKATA-YANAGIMOTO M,SUEHARA Y,et al.Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma［J］.Cancer Science,2018,109(1):225-230.
［3］周道斌,张炎.原发中枢神经系统淋巴瘤诊治现状及进展［J］.山东大学学报（医学版），2019，57(7):31-39. ZHOU DB,ZHANG Y.Current status and progress of diagnosis and treatment of primary central nervous system lymphoma［J］.Journal of Shandong University(Health Sciences),2019,57(7):31-39.
［4］GRILLO P,GIULIANO FD,MASSA R,et al.Movement disorders in primary central nervous system lymphoma:two unreported cases and a review of literature［J］.Neurological Sciences,2021,42(3):905-910.
［5］CHEN T,LIU Y,WANG Y,et al.Evidence-based expert consensus on the management of primary central nervous system lymphoma in China［J］.Hematol Oncol,2022,15(1):136.
［6］VU K,MANNIS G,HWANG J,et al.Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma［J］.British Journal of Haematology,2019,186(1):180-183.
［7］SHI K,SHEN J,YUE X.Primary central nervous system lymphoma with symmetrical pyramidal tract hyperintensity［J］.JAMA Neurology,2021,78(21):876-877.
［8］GERALD I,ELISABETH S,BENJAMIN K.Novel agents for primary central nervous system lymphoma:evidence and perspectives［J］.Blood,2018,132(7):681-688.
［9］SCHMITZ R,WRIGHT GW,HUANG DW,et al.Genetics and pathogenesis of diffuse large B-cell lymphoma［J］.N Engl J Med,2018,378(15):1396-1407.
［10］ZHU Q,WANG J,ZHANG W,et al.Whole-genome/exome sequencing uncovers mutations and copy number variations in primary diffuse large B-cell lymphoma of the central nervous system［J］.Front Genet,2022,13:878618.
［11］杜晓刘，刘冲，肖璇，等.原发性中枢神经系统T细胞淋巴瘤临床病理学分析［J］.中华病理学杂志，2020，49(3):228-233. DU XL,LIU C,XIAO X,et al.Clinicopathological features of primary central nervous system T-cell lymphomas［J］.Chinese Journal of Pathology,2020,49(3):228-233.
［12］刘诤，张鹏帅，宋子木，等.原发性中枢神经系统淋巴瘤的临床特征及影响预后的相关因素［J］.临床神经外科杂志，2021，18(4):419-423. LIU Z,ZHANG PS,SONG ZM,et al.Clinical characteristics and prognostic factors of primary central nervous system lymphoma［J］.Journal of Clinical Neurosurgery,2021,18(4):419-423.
［13］CHAN CC,RUBENSTEIN JL,COUPLAND SE,et al.Primary vitreoretinal lymphoma:a report from an International Primary Central Nervous System BATCHELOR 17 Lymphoma Collaborative Group symposium［J］.Oncologist,2011,16(11):1589-1599.
［14］葛岩，林兴滔，罗东兰，等.原发性中枢神经系统淋巴瘤62例临床病理学特征及预后［J］.中华病理学杂志，2019，48(11):861-866. GE Y,LIN XT,LUO DL,et al.Clinical features and treatment outcomes in primary central nervous system lymphoma:a descriptive analysis of 62 patients［J］.Chinese Journal of Hematology,2019,48(11):861-866.
［15］GRAHAM MS,DEANGELIS LM.Improving outcomes in primary CNS lymphoma［J］.Best Pract Res Clin Haematol,2018,31(3):262-269.
［16］FERRERI AJM,CWYNARSKI K,PULCZYNSKI E,et al.Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma:results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial［J］.Lancet Haematol,2017,4(11):e510-e523.
［17］BROMBERG JEC,ISSA S,BAKUNINA K,et al.Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24):a randomised,open-label,phase 3 intergroup study［J］.Lancet Oncol,2019,20(2):216-228.
［18］YIXIAN GUO.Abstract 1416:Ibrutinib in combination with rituximab and high-dose methotrexate in newly diagnosed primary central nervous system lymphoma patients［C］.2021ASH.
［19］宋嘉,刘惠,沈红利,等.新诊断原发中枢神经系统弥漫大B细胞淋巴瘤49例临床特征及预后分析［J］.中华血液学杂志,2021,42(11):917-922. SONG J,LIU H,SHEN HL,et al.Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma［J］.Chinese Journal of Hematology,2021,42(11):917-922.

Memo

Memo:
陕西省自然科学基金(编号：2020JQ-460）
Last Update: 1900-01-01